LNAI
Lunai BioworksFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Clinical proof-of-concept or a favorable partnership could unlock sizeable upside given the current low market capitalization and limited analyst coverage; expectation is material re-rating toward biotech peers on positive data.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Trial failure, extended cash runway concerns, or dilutive financing could push the stock materially lower; illiquidity can exacerbate downside on negative headlines.
Momentum
8
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.06 · Bull $1.60 · Bear $0.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum8 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
8
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 8.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$13.51M
Beta
0.45
Shares Out
23.43M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.45
Rev YoY
-
EPS YoY
+104.4%
Gross Margin
-
Op Margin
-
Net Debt
$8.96M
Current Ratio
0.04
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology